Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients

NCT06645678 is registered in ClinicalTrials.gov with YOUNGIL KOH as lead sponsor.

NCT NCT06645678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06645678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Mezigdomide and Elranatamab for Relapsed/Refractory Multiple Myeloma Patients
Lead sponsor
YOUNGIL KOH
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 26, 2024
Completion date
October 1, 2027
Enrollment
75 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory multiple myeloma (rrmm)